Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases.
Samuel BitounJulien HenryDelphine DesjardinsChristelle Vauloup-FellousNicolas DibRakiba BelkhirLina MounaCandie JolyMarie BituBineta LyJuliette PascaudRaphaèle SerorAnne-Marie Roque AfonsoRoger Le GrandXavier MariettePublished in: Arthritis & rheumatology (Hoboken, N.J.) (2022)
RTX induced a diminished antibody response to the mRNA COVID-19 vaccine, but the functional T cell response was not altered compared to healthy controls and autoimmune disease patients treated with other immunosuppressants. Further work is needed to assess the clinical protection granted by a functionally active T cell response in the absence of an anti-spike antibody response.